Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewLY 233053
Description: Competitive NMDA antagonist
Chemical Name: (2R*,4S*)-4-(1H-Tetrazol-5-ylmethyl)-2-piperidinecarboxylic acid
Purity: ≥99% (HPLC)
Biological Activity for LY 233053
LY 233053 is a competitive NMDA receptor antagonist (IC50 = 7 nM) that displays no affinity for AMPA or kainate receptors at a concentration of 10 μM. Inhibits NMDA-induced neuronal degeneration and protects from NMDA-induced convulsions in neonatal rats.
Licensing Information
Sold with the permission of Eli Lilly and Company
Technical Data for LY 233053
| M. Wt | 211.22 |
| Formula | C8H13N5O2 |
| Storage | Desiccate at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 125546-04-5 |
| PubChem ID | 90479799 |
| InChI Key | RTVQJOXSBRCZBN-JUKSSJACSA-N |
| Smiles | O=[C@@]([C@@H]1C[C@H](CC2=NN=NN2)CCN1)O.O=C([C@H]3C[C@@H](CC4=NN=NN4)CCN3)O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for LY 233053
References for LY 233053
References are publications that support the biological activity of the product.
Schoepp et al (1990) Pharmacological characterization of LY233053: a structurally novel tetrazole-substituted competitive N-MthD.-aspartic acid antagonist with a short duration of action. J.Pharmacol.Exp.Ther. 255 1301 PMID: 2148188
Madden et al (1992) Efficacy of LY233053, a competitive glutamate antagonist, in experimental central nervous system ischemia. J.Neurosurg. 76 106 PMID: 1727148
Madden et al (1993) Delayed therapy of experimental ischemia with competitive N-MthD.-aspartate antagonists in rabbits. Stroke 24 1068 PMID: 8322381
View Related Products by Target
View Related Products by Product Action
Keywords: LY 233053, LY 233053 supplier, Competitive, NMDA, receptor, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGlur, Ionotropic, LY233053, 1521, Tocris Bioscience
Citations for LY 233053
Citations are publications that use Tocris products.
Currently there are no citations for LY 233053.
Reviews for LY 233053
There are currently no reviews for this product. Be the first to review LY 233053 and earn rewards!
Have you used LY 233053?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.